← Eichor
Condition: Tp53 Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Tp53 Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Li-Fraumeni Syndrome/TP53 Biobank
Phase N/A · 2 location(s) · Abramson Cancer Center at Penn Medicine · NCT04367246Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06413992Germline Genetic Testing of the TP53 Gene
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07419893Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Nerviano Medical Sciences · NCT06549790Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNN
NA · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06718153A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06908434A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, R
Phase 1 · 5 location(s) · PMV Pharmaceuticals, Inc · NCT07372625Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With
Phase 3 · 242 location(s) · National Cancer Institute (NCI) · NCT07198074Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Phase 2 · 2 location(s) · Sun Yat-sen University · NCT06517511ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Phase 3 · 4 location(s) · Newave Pharmaceutical Inc · NCT07342478Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-
Phase 1/Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT07008638A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H
Phase 1 · 18 location(s) · AstraZeneca · NCT05877599Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Phase 1 · 4 location(s) · Washington University School of Medicine · NCT06795009Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07499271JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Phase 1/Phase 2 · 15 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06386146Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06778187MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Phase N/A · 2 location(s) · Mohammad H. Abu Arja · NCT07242963Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Phase 3 · 1 location(s) · Qianfoshan Hospital · NCT06043973A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP
Phase 1/Phase 2 · 2 location(s) · Nutshell Therapeutics (Shanghai) Co., LTD. · NCT07060989Clinical and Genetic Studies of Li-Fraumeni Syndrome
Phase N/A · 2 location(s) · National Cancer Institute (NCI) · NCT01443468Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
Phase N/A · 3 location(s) · Dana-Farber Cancer Institute · NCT04541654The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/Phase 2 · 77 location(s) · PMV Pharmaceuticals, Inc · NCT04585750AZA Combined With RCHOP in P53-mutated DLBCL.
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06158399A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 · 21 location(s) · Clasp Therapeutics, Inc. · NCT06778863
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.